MDFI is a novel biomarker for poor prognosis in LUAD
Sign Up to like & getrecommendations! Published in 2022 at "Frontiers in Oncology"
DOI: 10.3389/fonc.2022.1005962
Abstract: Background Approximately 80% of lung cancers are non-small cell lung cancers (NSCLC). Lung adenocarcinoma (LUAD) is the main subtype of NSCLC. The incidence and mortality of lung cancer are also increasing yearly. Myogenic differentiation family… read more here.
Keywords: prognosis; prognosis luad; expression; poor prognosis ... See more keywords